Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma (MIC-VADS)
Head and neck squamous cell carcinoma (HNSCC), France's 5th most common cancer (15,000 annual cases), presents significant public health challenges due to high morbidity and functional/aesthetic sequelae from treatments (mutilating surgery, radiotherapy, chemotherapy). Major risk factors, tobacco and alcohol, create a chronic inflammatory environment promoting tumor development. The upper aerodigestive tract microbiome, influenced by these exposures and local alterations (necrosis, bleeding, ulcerations), is emerging as a potential factor in tumor progression, severity biomarker, or therapeutic target, though its exact role (cause or consequence) remains to be elucidated
Objectives:
- Primary: Compare bacterial microbiome composition between tumor tissue, adjacent healthy mucosa, and pharyngeal secretions
- Secondary:
- Correlate microbiome diversity/composition with clinical and epidemiological characteristics
- Identify microbiome variations by tumor stage, histology, and infiltration
- Discover diagnostic/prognostic microbial markers
- Analyze somatic variants (SNP/CNV) via whole-genome sequencing (WGS) and their association with microbiome profiles and clinical parameters
Study Design: Prospective, cross-sectional study with paired design (each patient serves as their own control to minimize genetic variation biases)
Methods:
- Samples: Tumor, adjacent healthy tissue, and pharyngeal secretions (3 samples/patient)
- Sequencing: Metagenomic sequencing (complete bacterial genomes) when biomass permits, or targeted 16S rRNA sequencing to identify dominant genera.
- Pilot study: 20 patients to select the optimal technique and validate feasibility, particularly assessing DNA quantity in these low-biomass environments
Population: Adults with suspected HNSCC scheduled for panendoscopy
Exclusion criteria: Recent antibiotics/corticosteroids (12 weeks), immunosuppression (uncontrolled HIV, active hematologic malignancies, autoimmune diseases on immunosuppressants, organ/stem cell transplants, uncontrolled diabetes), immunomodulatory treatments (3 months), recurrence, pregnancy, non-French speakers, legal guardianship, or lack of social security.
Safety: No additional risks beyond standard panendoscopy.
Expected impact: This approach may pave the way for innovative diagnostic or therapeutic strategies based on microbiome modulation in HNSCC.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Caroline TOURTE
- Phone Number: +33 01 61 69 31 50
- Email: caroline.tourte@chsf.fr
Study Contact Backup
- Name: Renato TORRES, MD
- Phone Number: +33 01 61 69 34 59
- Email: renato.torres-lazo@chsf.fr
Study Locations
-
-
France
-
Corbeil-Essonnes, France, France, 91100
- Centre Hospitalier Sud Francilien
-
Contact:
- Renato TORRES, MD
- Phone Number: +33 01 61 69 34 59
- Email: renato.torres-lazo@chsf.fr
-
Principal Investigator:
- Renato TORRES, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patient
- Consultation in the ENT department for suspected squamous cell carcinoma of the upper aerodigestive tract scheduled for panendoscopy
- Patient has provided consent to participate in the study and signed an informed consent form
Exclusion Criteria:
-
Antibiotic or corticosteroid therapy within 12 weeks prior to consultation
-
Conditions associated with immunosuppression:
- Uncontrolled HIV infection (CD4 < 200 cells/µL) (permanent exclusion)
- Hematologic malignancies currently under treatment or not in complete remission for <2 years
- Autoimmune diseases under immunosuppressive treatment
- Solid organ or stem cell transplant recipients (permanent exclusion)
- Poorly controlled diabetes (HbA1c > 9%)
-
Immunomodulatory treatment within 3 months prior to consultation:
- Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4)
- Biotherapy targeting the immune system (anti-TNF, anti-IL, calcineurin inhibitors, antimetabolites)
- Recurrent upper aerodigestive tract cancer previously treated with surgery and/or radiochemotherapy
- Pregnancy (confirmed prior to panendoscopy)
- Patient who does not speak or understand French
- Subject under guardianship or curatorship
- Subject not affiliated with the national health insurance system
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Microbiome in head and neck squamous cell carcinoma Patients
Patients with suspected head and neck squamous cell carcinoma undergoing panendoscopy with additional biopsy sampling of tumor tissue, adjacent healthy mucosa, and pharyngeal secretions for microbiome analysis |
Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:
These samples are used for microbiome analysis. head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention. Additional biopsies (beyond standard clinical practice) taken during panendoscopy to collect:
These samples are used for microbiome analysis. head and neck squamous cell carcinoma Note: The panendoscopy itself is a standard clinical procedure, but the additional biopsies for research purposes represent the study-specific intervention. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The difference in bacterial composition between the tumor, healthy mucosa, and hypopharyngeal secretions will be assessed
Time Frame: at day 1
|
at day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in the tumor microbiome between subgroups defined by tumor stage, histological type, or infiltration, using differentiation tests
Time Frame: at day 1
|
at day 1
|
|
|
Differential bacterial genera or strains between tumor, healthy, and pharyngeal microbiomes
Time Frame: at day 1
|
at day 1
|
|
|
Correlations between tumor microbiome diversity and composition and clinical/epidemiological data
Time Frame: at day 1
|
tumor microbiome diversity (by sequencing) tumor microbiome composition (by sequencing) |
at day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Béatrice SEGURENS, Phd, HDR
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2026-A00392-49
- 2026/0003 (Other Identifier: CHSF)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.